Eloxx Pharmaceuticals Company

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases.
Technology: Biotechnology
Industry: Personalized Medicine
Headquarters: Waltham, Massachusetts, USA
Founded Date: 2013
Employees Number: 10-50
Funding Status: IPO

Visit Website
Register and Claim Ownership